Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Norwich
Clinical trial register · United Kingdom · industry-sponsored

Clinical Trials in Norwich, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a UK site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full UK registry across all sponsors is far larger. UK studies may also be registered separately on ISRCTN.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 2863 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 12 Oct 2026, 03:15 UTC
2863
Studies in scope
industry-sponsored, all four open statuses
1385
Recruiting now
open to new participants
542
Lead sponsors
across recruiting studies
Top sites
London 2015 Manchester 668 Birmingham 478 Glasgow 437 Cambridge 425
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca7 BeOne Medicines4 AbbVie4 Regeneron Pharmaceuticals3 Janssen Research & Development, LLC3
Site city
London2015 Manchester668 Birmingham478 Glasgow437 Cambridge425
All 429 cities
Target enrolment
to

Trials with a site in Norwich

59 of 2863 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
UK sites
Start
Recruiting
ModernaTX, Inc.
Phase 1
375
Manchester, Southampton, Norwich, Birmingham, London, Newcastle
2026-08-11
Recruiting
Regeneron Pharmaceuticals
Phase 3
270
Truro, Norwich, Leicester
2026-05-21
Recruiting
Ipsen
Phase 3
350
Frimley, London, Norwich, Oxford, Cottingham, Aberdeen, Birmingham, Glasgow
2026-05-14
Recruiting
Novo Nordisk A/S
Phase 3
5,610
Truro, Rhyl, Torquay, Dorchester, Airdrie, Tooting, Isleworth, Norwich
2026-05-11
Recruiting
UK PureWick™ At-Home Pilot Study
NCT07555548Urinary Incontinence
Becton, Dickinson and Company
Observational
95
Doncaster, Leicester, Northampton, Norwich
2026-05-06
Recruiting
Janssen Research & Development, LLC
Phase 3
530
Greater London, Iselworth, London, Norwich, Wolverhampton
2026-04-21
Recruiting
Incyte Corporation
Phase 3
588
Dundee, Guildford, Headington, Leeds, London, Manchester, Northwood, Norwich
2026-04-09
Recruiting
Bristol-Myers Squibb
Phase 3
750
Aberdeen, Middlesbrough, Norwich, Sutton, Cambridge, Cardiff, Guildford, London
2026-03-12
Recruiting
Peptilogics
Phase 2/3
240
Cambridge, Edinburgh, Norwich, Leeds
2026-02-03
Recruiting
AbbVie
Phase 2
165
Cambridge, Edinburgh, London, Southampton, Norwich
2026-01-23
Recruiting
CSL Behring
Phase 2
84
Glasgow, Belfast, Bristol, Liverpool, London, Norwich, Nottingham, Oxford
2026-01-22
Recruiting
BeOne Medicines
Phase 3
500
Birmingham, Bournemouth, Leeds, London, Norwich
2026-01-22
Recruiting
Regeneron Pharmaceuticals
Phase 3
915
Aberdeen, Truro, Plymouth, Norwich, Birmingham, Dundee
2026-01-02
Recruiting
Bristol-Myers Squibb
Phase 2/3
990
Norwich, Manchester, Metropolitan Borough of Wirral, Oxford, Guildford, Birmingham, Cardiff, Dorchester
2025-12-31
Recruiting
AstraZeneca
Phase 3
400
Huddersfield, London, Maidstone, Norwich, Stoke-on-Trent
2025-10-31
Recruiting
Gesynta Pharma AB
Phase 2
190
Bradford, Bristol, Corby, Coventry, London, Northwood, Norwich, Orpington
2025-10-15
Recruiting
Sanofi
Phase 3
980
Cottingham, Cambridge, London, Norwich, Rochdale
2025-10-01
Recruiting
Merck Sharp & Dohme LLC
Phase 2
315
Norwich, Bath, Barnet, Bradford
2025-09-26
Recruiting
Sanofi
Phase 3
124
London, Norwich, Oxford
2025-09-26
Recruiting
BeOne Medicines
Phase 3
500
Brighton, Canterbury, Norwich, Oxford, Roundhay, Salisbury
2025-09-04
Recruiting
AstraZeneca
Phase 2
100
Bristol, Dundee, Headington, London, Norwich
2025-07-17
Recruiting
Pfizer
Phase 2
620
Dundee, London, Norwich, Chichester, Belfast, High Wycombe
2025-06-19
Recruiting
AstraZeneca
Phase 3
11,300
Aberdeen, Chesterfield, Dundee, Gatley, Glasgow, London, Norwich, Penzance
2025-03-14
Recruiting
Ascendis Pharma A/S
Phase 2
24
Norwich
2024-12-10
Recruiting
Merck Sharp & Dohme LLC
Phase 3
3,082
Bristol, Exeter, Newcastle, Norwich, Northamptonshire, Bicester, Oxford, Somerset
2024-12-02
Recruiting
Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
NCT06526793B-cell Non-Hodgkin Lymphoma, Follicular Lymphoma (FL), Large B-Cell Lymphoma (LBCL)
DrugSurovatamig
AstraZeneca
Phase 2
270
London, Manchester, Norwich, Nottingham, Plymouth
2024-11-27
Recruiting
AbbVie
Phase 3
110
Cambridge, Sheffield, London, Norwich, Edinburgh
2024-08-08
Recruiting
AstraZeneca
Phase 3
1,018
London, Newcastle upon Tyne, Norwich, Nottingham, Plymouth, Southampton
2024-08-07
Active, closed
Janssen Research & Development, LLC
Phase 1
108
London, Manchester, Norwich, Plymouth
2024-06-07
Active, closed
INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC
NCT06295731Head and Neck Squamous Cell Carcinoma (HNSCC)
DrugsKeytruda·Pembrolizumab
Inhibrx Biosciences, Inc
Phase 2/3
410
Chelsea, Northwood, Newcastle upon Tyne, Sutton, Aberdeen, Cambridge, Manchester, Norwich
2024-05-14
Recruiting
AstraZeneca
Phase 3
675
Cheltenham, Inverness, London, Norwich, Preston, Truro
2024-04-11
Active, closed
Xentria, Inc.
Phase 2
31
Coventry, London, Norwich, Perth
2024-03-01
Active, closed
AstraZeneca
Phase 2
108
Birmingham, Gloucester, London, Norwich, Nottingham, Plymouth
2023-12-13
Recruiting
Regeneron Pharmaceuticals
Phase 3
822
Truro, Plymouth, Bournemouth, Glasgow, Norwich, Romford
2023-12-12
Active, closed
Syndax Pharmaceuticals
Phase 2
145
Cambridge, Norwich, Oxford, Perth, Leeds, Birmingham
2023-12-11
Active, closed
Gilead Sciences
Phase 2
176
Bury, Cambridge, London, Norwich, Southampton
2023-12-05
Active, closed
BeOne Medicines
Phase 3
652
Bournemouth, Canterbury, Headington, Leeds, Liverpool, London, Norwich, Southampton
2023-11-11
Active, closed
Xentria, Inc.
Phase 1/2
32
Coventry, London, Norwich, Oxford, Perth
2023-11-10
Recruiting
PlaqueTec Ltd
Not applicable
300
Bournemouth, Bristol, Cambridge, Norwich
2023-09-14
Active, closed
Alfasigma S.p.A.
Observational
509
Belfast, Bury, Exeter, Glasgow, London, Norwich, Oxford, Southampton
2023-06-12
Active, closed
Evaluation of the Safety and Efficacy of Eneboparatide (AZP-3601) in Patients With Chronic Hypoparathyroidism
NCT05778071Chronic Hypoparathyroidism, Endocrine System Diseases, Parathyroid Diseases
Alexion Pharmaceuticals, Inc.
Phase 3
165
Leicester, Norwich, Oxford
2023-06-07
Active, closed
Alfasigma S.p.A.
Phase 3
495
Bath, Norwich
2023-04-05
Recruiting
Eupraxia Pharmaceuticals Inc.
Phase 1/2
117
Norwich, Cardiff, Liverpool, London
2023-03-31
Active, closed
Janssen Research & Development, LLC
Phase 3
614
Aberdeen, Birmingham, Colchester, Liverpool, London, Middlesbrough, Norwich, Staffordshire
2023-03-29
Active, closed
ModernaTX, Inc.
Phase 1
186
Norwich
2023-02-15
Active, closed
Genmab
Phase 3
900
Birmingham, London, Norwich, Edinburgh
2023-02-08
Active, closed
Calcilytix Therapeutics, Inc., a BridgeBio company
Phase 3
67
Newcastle upon Tyne, Norwich
2023-01-06
Recruiting
Post-Market Study to Assess iTind Safety in Comparison to UroLift
NCT04757116Benign Prostatic Hyperplasia (BPH)
Olympus Corporation of the Americas
Not applicable
256
Isleworth, Dunfermline, London, Norwich
2022-09-26
Active, closed
Sanofi
Phase 3
531
Derby, Birmingham, Leicester, London, Norwich
2022-06-23
Active, closed
Geko™ Cross Therapy Registry - Wound
NCT05007301Wound, Venous Leg Ulcer, Diabetic Foot Ulcer, Arterial Leg Ulcer
Firstkind Ltd
Observational
2,500
London, Norwich
2022-04-04
Recruiting
AbbVie
Phase 2
75
Blackpool, Norwich, Leeds
2022-03-28
Active, closed
Boston Scientific Corporation
Not applicable
500
Guildford, Cardiff, Belfast, Bristol, London, Norwich, Plymouth
2021-12-21
Recruiting
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
NCT05006716B-cell Malignancy, Marginal Zone Lymphoma, Follicular Lymphoma, Non-Hodgkin Lymphoma
DrugTacabrutideg
BeOne Medicines
Phase 1/2
689
Edinburgh, Leeds, Newcastle upon Tyne, Newmarket, Norwich, Nottingham, Plymouth
2021-09-13
Active, closed
Loxo Oncology, Inc.
Phase 3
238
Aberdeen, Truro, Plymouth, Cottingham, London, Norwich, Swansea, Edinburgh
2021-03-09
Active, closed
Comparing UroLift Experience Against Rezūm
NCT04338776Benign Prostatic Hyperplasia
NeoTract, Inc.
Not applicable
120
Frimley, Norwich, Cambridge
2021-01-22
Active, closed
Genmab
Phase 3
483
Birmingham, London, Norwich, Nottingham, Plymouth, Southampton, Sutton, Truro
2021-01-13
Active, closed
A Clinical Efficacy and Safety Study of OHB-607 in Preventing Bronchopulmonary Dysplasia in Extremely Premature Infants
NCT03253263Bronchopulmonary Dysplasia, Chronic Lung Disease of Prematurity, Intraventricular Hemorrhage, Retinopathy of Prematurity (ROP)
OHB Neonatology Ltd.
Phase 2
295
Norwich, Chertsey, Cambridge, Coventry, Liverpool, London, Manchester
2019-05-09
Recruiting
Abbott Medical Devices
Observational
2,000
Norwich, Liverpool, Bristol, Leeds
2019-03-13
Active, closed
AbbVie
Phase 3
265
Cambridge, London, Norwich, Nottingham, Glasgow, Stoke-on-Trent, Manchester, Portsmouth
2018-10-22
Rows per page Showing 1–59 of 59
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a UK investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 12 October 2026. https://priyalifescience.com/clinical-trials-uk/city/norwich

Query this register directly
GET /api/trials?country=uk&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the UK and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 2,863 studies in total at the last sync on 12 Oct 2026, 03:15 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 59 of those studies with a site in Norwich.

How many clinical trials are recruiting in Norwich?

36 of the 59 studies on this page are recruiting new participants as of the 12 Oct 2026, 03:15 UTC sync. A further 0 have not yet opened recruitment, 23 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Norwich), 59 studies
PhaseStudiesRecruitingShare
Phase 3281847.5%
Phase 214923.7%
Not applicable426.8%
Observational426.8%
Phase 1315.1%
Phase 1/2325.1%
Phase 2/3325.1%

Most active sponsors

Lead sponsors with the most studies (Norwich)
Lead sponsorStudiesRecruiting
AstraZeneca76
AbbVie43
BeOne Medicines43
Janssen Research & Development, LLC31
Regeneron Pharmaceuticals33
Sanofi32
Alfasigma S.p.A.20
Bristol-Myers Squibb22
Genmab20
Merck Sharp & Dohme LLC22
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the UK Pharma Salary Guide, or see the Ireland, EU and USA registers.